ArticleJournal of endocrinological investigation2026
Novel biomarkers to guide glucocorticoid replacement in primary adrenal insufficiency: a proof-of-concept study using copeptin-derived ratios.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOptimising glucocorticoid (GC) replacement in primary adrenal insufficiency (PAI) remains challenging, as clinical and biochemical markers do not reliably mirror tissue cortisol exposure.
objectiveTo evaluate salivary cortisone exposure and copeptin-derived ratios as candidate biomarkers of GC replacement adequacy in PAI.
designCross-sectional case-control study with 12-month follow-up including nineteen adults with autoimmune or idiopathic PAI on stable hydrocortisone (HC; immediate- or dual-release) plus fludrocortisone, and forty-three healthy controls.
methodsSix daytime saliva samples were collected for cortisol and cortisone quantification by LC-MS/MS. The area-under-the-curve (AUC) of cortisone was computed, and patients were classified as GC excess (AUC above the 90th percentile of controls; Group A) or adequate replacement (10th-90th percentile; Group B). Plasma ACTH, copeptin, renin, electrolytes and osmolarity were measured fasting and 120 min post-dose.
resultsAt baseline, 31.6% of patients showed GC excess, increasing to 36.8% at follow-up. Compared with Group B, Group A exhibited higher HbA1c (46.5 vs. 34.0 mmol/mol, p < 0.05) and diastolic blood pressure (84.5 ± 8.7 vs. 77.0 ± 9.6 mmHg, p < 0.05) with lower pulse pressure. ACTH and ACTH/copeptin ratios were markedly reduced in Group A both fasting (median 38.1 vs. 132.4) and post-dose (12.9 vs. 41.6), while renin/copeptin ratios declined at T1. ACTH/copeptin correlated inversely with cortisone AUC (r = - 0.59, p < 0.01).
conclusionsSalivary cortisone AUC, together with ACTH/copeptin and renin/copeptin ratios, identifies physiologically distinct GC exposure profiles linked to metabolic and haemodynamic alterations. These biomarkers may refine personalised GC replacement in PAI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.